Receptor conformation and constitutive activity in CCR5 chemokine receptor function and HIV infection

Advances in Pharmacology

Volumn 70, Issue , 2014, Pages 215-263

  Flanagan, Colleen A ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

CCR5 blockers; CCR5 chemokine receptor; Conformation; HIV coreceptor

Indexed keywords

BETA ARRESTIN; CALCIUM; CARBON TETRACHLORIDE; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHOLESTEROL; CLATHRIN; FOCAL ADHESION KINASE 2; G ALPHA I PROTEIN; G ALPHA Q PROTEIN; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; INTERLEUKIN 1BETA; JANUS KINASE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCLONAL ANTIBODY; PERTUSSIS TOXIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PHOSPHOLIPASE C; PROTEIN; RANTES; STAT5 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS ENVELOPE PROTEIN;

ACTIN FILAMENT; AMINO TERMINAL SEQUENCE; ANTIGEN PRESENTING CELL; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; APOPTOSIS; ARTICLE; BINDING AFFINITY; BINDING SITE; CALCIUM MOBILIZATION; CALCIUM TRANSPORT; CANCER CELL LINE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CELL SURFACE; CYTOKINE RELEASE; CYTOSKELETON; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FLUORESCENCE RECOVERY AFTER PHOTOBLEACHING; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INTERNALIZATION; LEUKOCYTE ACTIVATION; MACROPHAGE; MEMBRANE FUSION; MICROGLIA; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PATHOGENESIS; PDZ DOMAIN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TRANS GOLGI NETWORK; VIRUS ENTRY; VIRUS LOAD; VIRUS REPLICATION; WILD TYPE; AGONISTS; CHEMISTRY; GENETICS; INVERSE AGONISM; METABOLISM; MUTATION; VIROLOGY;

CCR5 RECEPTOR ANTAGONISTS; DRUG INVERSE AGONISM; HIV INFECTIONS; HUMANS; MUTATION; PROTEIN CONFORMATION; RECEPTORS, CCR5; VIRUS INTERNALIZATION;

EID: 84902145874     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/B978-0-12-417197-8.00008-0     Document Type: Chapter

References (240)

1. Achour L., Scott M.G., Shirvani H., Thuret A., Bismuth G., Labbe-Jullie C., et al. CD4-CCR5 interaction in intracellular compartments contributes to receptor expression at the cell surface. Blood 2009, 113:1938-1947.
2. Ahuja S., Smith S.O. Multiple switches in G protein-coupled receptor activation. Trends in Pharmacological Sciences 2009, 30:494-502.
3. Amara A., Vidy A., Boulla G., Mollier K., Garcia-Perez J., Alcami J., et al. G protein-dependent CCR5 signaling is not required for efficient infection of primary T lymphocytes and macrophages by R5 human immunodeficiency virus type 1 isolates. Journal of Virology 2003, 77:2550-2558.
4. Anand A.R., Zhao H., Nagaraja T., Robinson L.A., Ganju R.K. N-terminal Slit2 inhibits HIV-1 replication by regulating the actin cytoskeleton. Retrovirology 2013, 10:2.
5. Aramori I., Ferguson S.S., Bieniasz P.D., Zhang J., Cullen B., Cullen M.G. Molecular mechanism of desensitization of the chemokine receptor CCR-5: Receptor signaling and internalization are dissociable from its role as an HIV-1 co-receptor. EMBO Journal 1997, 16:4606-4616.
6. Ardura J.A., Friedman P.A. Regulation of G protein-coupled receptor function by Na+/H+exchange regulatory factors. Pharmacological Reviews 2011, 63:882-900.
7. Arias D.A., Navenot J.M., Zhang W.B., Broach J., Peiper S.C. Constitutive activation of CCR5 and CCR2 induced by conformational changes in the conserved TXP motif in transmembrane helix 2. The Journal of Biological Chemistry 2003, 278:36513-36521.
8. Arrildt K.T., Joseph S.B., Swanstrom R. The HIV-1 env protein: A coat of many colors. Current HIV/AIDS Reports 2012, 9:52-63.
9. Arthos J., Rubbert A., Rabin R.L., Cicala C., Machado E., Wildt K., et al. CCR5 signal transduction in macrophages by human immunodeficiency virus and simian immunodeficiency virus envelopes. Journal of Virology 2000, 74:6418-6424.
10. Baba M., Nishimura O., Kanzaki N., Okamoto M., Sawada H., Iizawa Y., et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:5698-5703.
11. Bachelerie F., Ben-Baruch A., Burkhardt A.M., Combadiere C., Farber J.M., Graham G.J., et al. International Union of Pharmacology. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacological Reviews 2014, 66:1-79.
12. Bain J., Plater L., Elliott M., Shpiro N., Hastie C.J., McLauchlan H., et al. The selectivity of protein kinase inhibitors: A further update. The Biochemical Journal 2007, 408:297-315.
13. Baker A.M., Sauliere A., Gaibelet G., Lagane B., Mazeres S., Fourage M., et al. CD4 interacts constitutively with multiple CCR5 at the plasma membrane of living cells. A fluorescence recovery after photobleaching at variable radii approach. The Journal of Biological Chemistry 2007, 282:35163-35168.
14. Barouch D.H., Klasse P.J., Dufour J., Veazey R.S., Moore J.P. Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:8694-8698.
15. Berger E.A., Murphy P.M., Farber J.M. Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease. Annual Review of Immunology 1999, 17:657-700.
16. Berro R., Klasse P.J., Lascano D., Flegler A., Nagashima K.A., Sanders R.W., et al. Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors. Journal of Virology 2011, 85:8227-8240.
17. Berro R., Yasmeen A., Abrol R., Trzaskowski B., Abi-Habib S., Grunbeck A., et al. Use of G-protein-coupled and -uncoupled CCR5 receptors by CCR5 inhibitor-resistant and -sensitive human immunodeficiency virus type 1 variants. Journal of Virology 2013, 87:6569-6581.
18. Blanpain C., Vanderwinden J.M., Cihak J., Wittamer V., Le Poul E., Issafras H., et al. Multiple active states and oligomerization of CCR5 revealed by functional properties of monoclonal antibodies. Molecular Biology of the Cell 2002, 13:723-737.
19. Blumenthal R., Durell S., Viard M. HIV entry and envelope glycoprotein-mediated fusion. The Journal of Biological Chemistry 2012, 287:40841-40849.
20. Boesecke C., Pett S.L. Clinical studies with chemokine receptor-5 (CCR5)-inhibitors. Current Opinion in HIV and AIDS 2012, 7:456-462.
21. Brandt S.M., Mariani R., Holland A.U., Hope T.J., Landau N.R. Association of chemokine-mediated block to HIV entry with coreceptor internalization. The Journal of Biological Chemistry 2002, 277:17291-17299.
22. Buontempo P.J., Wojcik L., Buontempo C.A., Ogert R.A., Strizki J.M., Howe J.A., et al. Quantifying the relationship between HIV-1 susceptibility to CCR5 antagonists and virus affinity for antagonist-occupied co-receptor. Virology 2009, 395:268-279.
23. Camargo J.F., Quinones M.P., Mummidi S., Srinivas S., Gaitan A.A., Begum K., et al. CCR5 expression levels influence NFAT translocation, IL-2 production, and subsequent signaling events during T lymphocyte activation. Journal of Immunology 2009, 182:171-182.
24. Camps M., Carozzi A., Schnabel P., Scheer A., Parker P.J., Gierschik P. Isozyme-selective stimulation of phospholipase C-beta 2 by G protein beta gamma-subunits. Nature 1992, 360:684-686.
25. Capalbo G., Mueller-Kuller T., Markovic S., Klein S.A., Dietrich U., Hoelzer D., et al. Knockdown of ERM family member moesin in host cells increases HIV type 1 replication. AIDS Research and Human Retroviruses 2011, 27:1317-1322.
26. Cardaba C.M., Mueller A. Distinct modes of molecular regulation of CCL3 induced calcium flux in monocytic cells. Biochemical Pharmacology 2009, 78:974-982.
27. Cardaba C.M., Kerr J.S., Mueller A. CCR5 internalisation and signalling have different dependence on membrane lipid raft integrity. Cellular Signalling 2008, 20:1687-1694.
28. Carter G.C., Bernstone L., Sangani D., Bee J.W., Harder T., James W. HIV entry in macrophages is dependent on intact lipid rafts. Virology 2009, 386:192-202.
29. Castellino F., Huang A.Y., Altan-Bonnet G., Stoll S., Scheinecker C., Germain R.N. Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature 2006, 440:890-895.
30. Charo I.F., Ransohoff R.M. The many roles of chemokines and chemokine receptors in inflammation. The New England Journal of Medicine 2006, 354:610-621.
31. Charo I.F., Hills R., Horuk R., Matsushima K., Murphy P.M., Oppenheim J.J. Chemokine receptors: CCR5 Last modified on 31 January 2013. IUPHAR database (IUPHAR-DB). Retrieved accessed on 22 July 2013. http://www.iuphar-db.org/DATABASE/ObjectDisplayForward?objectId=62.
32. Chen G., Way J., Armour S., Watson C., Queen K., Jayawickreme C.K., et al. Use of constitutive G protein-coupled receptor activity for drug discovery. Molecular Pharmacology 2000, 57:125-134.
33. Cheung R., Ravyn V., Wang L., Ptasznik A., Collman R.G. Signaling mechanism of HIV-1 gp120 and virion-induced IL-1beta release in primary human macrophages. Journal of Immunology 2008, 180:6675-6684.
34. Cheung R., Malik M., Ravyn V., Tomkowicz B., Ptasznik A., Collman R.G. An arrestin-dependent multi-kinase signaling complex mediates MIP-1beta/CCL4 signaling and chemotaxis of primary human macrophages. Journal of Leukocyte Biology 2009, 86:833-845.
35. Choe W., Volsky D.J., Potash M.J. Induction of rapid and extensive beta-chemokine synthesis in macrophages by human immunodeficiency virus type 1 and gp120, independently of their coreceptor phenotype. Journal of Virology 2001, 75:10738-10745.
36. Choi W.T., Nedellec R., Coetzer M., Colin P., Lagane B., Offord R.E., et al. CCR5 mutations distinguish N-terminal modifications of RANTES (CCL5) with agonist versus antagonist activity. Journal of Virology 2012, 86:10218-10220.
37. Cicala C., Arthos J., Ruiz M., Vaccarezza M., Rubbert A., Riva A., et al. Induction of phosphorylation and intracellular association of CC chemokine receptor 5 and focal adhesion kinase in primary human CD4+ T cells by macrophage-tropic HIV envelope. Journal of Immunology 1999, 163:420-426.
38. Cicala C., Arthos J., Selig S.M., Dennis G., Hosack D.A., Van Ryk D., et al. HIV envelope induces a cascade of cell signals in non-proliferating target cells that favor virus replication. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:9380-9385.
39. Cicala C., Arthos J., Martinelli E., Censoplano N., Cruz C.C., Chung E., et al. R5 and X4 HIV envelopes induce distinct gene expression profiles in primary peripheral blood mononuclear cells. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:3746-3751.
40. Cocchi F., DeVico A.L., Garzino-Demo A., Arya S.K., Gallo R.C., Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995, 270:1811-1815.
41. Cocchi F., DeVico A.L., Garzino-Demo A., Cara A., Gallo R.C., Lusso P. The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nature Medicine 1996, 2:1244-1247.
42. Colin P., Benureau Y., Staropoli I., Wang Y., Gonzalez N., Alcami J., et al. HIV-1 exploits CCR5 conformational heterogeneity to escape inhibition by chemokines. Proceedings of the National Academy of Sciences of the United States of America 2013, 110:9475-9480.
43. Combadiere C., Ahuja S.K., Tiffany H.L., Murphy P.M. Cloning and functional expression of CC CKR5, a human monocyte CC chemokine receptor selective for MIP-1(alpha), MIP-1(beta), and RANTES. Journal of Leukocyte Biology 1996, 60:147-152.
44. Conti L., Fantuzzi L., Del Corno M., Belardelli F., Gessani S. Immunomodulatory effects of the HIV-1 gp120 protein on antigen presenting cells: Implications for AIDS pathogenesis. Immunobiology 2004, 209:99-115.
45. Corbeau P., Reynes J. CCR5 antagonism in HIV infection: Ways, effects, and side effects. AIDS 2009, 23:1931-1943.
46. Davis C.B., Dikic I., Unutmaz D., Hill C.M., Arthos J., Siani M.A., et al. Signal transduction due to HIV-1 envelope interactions with chemokine receptors CXCR4 or CCR5. The Journal of Experimental Medicine 1997, 186:1793-1798.
47. Dean M., Carrington M., Winkler C., Huttley G.A., Smith M.W., Allikmets R., et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996, 273:1856-1862.
48. Deeks S.G. HIV infection, inflammation, immunosenescence, and aging. Annual Review of Medicine 2011, 62:141-155.
49. Del Corno M., Liu Q.H., Schols D., de Clercq E., Gessani S., Freedman B.D., et al. HIV-1 gp120 and chemokine activation of Pyk2 and mitogen-activated protein kinases in primary macrophages mediated by calcium-dependent, pertussis toxin-insensitive chemokine receptor signaling. Blood 2001, 98:2909-2916.
50. Delhaye M., Gravot A., Ayinde D., Niedergang F., Alizon M., Brelot A. Identification of a postendocytic sorting sequence in CCR5. Molecular Pharmacology 2007, 72:1497-1507.
51. Deng H., Liu R., Ellmeier W., Choe S., Unutmaz D., Burkhart M., et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996, 381:661-666.
52. Deupi X., Kobilka B.K. Energy landscapes as a tool to integrate GPCR structure, dynamics, and function. Physiology (Bethesda) 2010, 25:293-303.
53. Deupi X., Standfuss J. Structural insights into agonist-induced activation of G-protein-coupled receptors. Current Opinion in Structural Biology 2011, 21:541-551.
54. de Voux A., Chan M.C., Folefoc A.T., Madziva M.T., Flanagan C.A. Constitutively active CCR5 chemokine receptors differ in mediating HIV envelope-dependent fusion. PLoS One 2013, 8:e54532.
55. Escola J.M., Kuenzi G., Gaertner H., Foti M., Hartley O. CC chemokine receptor 5 (CCR5) desensitization: Cycling receptors accumulate in the trans-Golgi network. The Journal of Biological Chemistry 2010, 285:41772-41780.
56. Fantuzzi L., Spadaro F., Purificato C., Cecchetti S., Podo F., Belardelli F., et al. Phosphatidylcholine-specific phospholipase C activation is required for CCR5-dependent, NF-kB-driven CCL2 secretion elicited in response to HIV-1 gp120 in human primary macrophages. Blood 2008, 111:3355-3363.
57. Farzan M., Choe H., Martin K.A., Sun Y., Sidelko M., Mackay C.R., et al. HIV-1 entry and macrophage inflammatory protein-1beta-mediated signaling are independent functions of the chemokine receptor CCR5. The Journal of Biological Chemistry 1997, 272:6854-6857.
58. Flanagan C.A. A GPCR that is not "DRY". Molecular Pharmacology 2005, 68:1-3.
59. Folefoc A.T., Fromme B.J., Katz A.A., Flanagan C.A. South African mutations of the CCR5 coreceptor for HIV modify interaction with chemokines and HIV Envelope protein. Journal of Acquired Immune Deficiency Syndromes 2010, 54:352-359.
60. Francois F., Klotman M.E. Phosphatidylinositol 3-kinase regulates human immunodeficiency virus type 1 replication following viral entry in primary CD4+ T lymphocytes and macrophages. Journal of Virology 2003, 77:2539-2549.
61. Gaertner H., Cerini F., Escola J.M., Kuenzi G., Melotti A., Offord R., et al. Highly potent, fully recombinant anti-HIV chemokines: Reengineering a low-cost microbicide. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:17706-17711.
62. Gaibelet G., Planchenault T., Mazeres S., Dumas F., Arenzana-Seisdedos F., Lopez A., et al. CD4 and CCR5 constitutively interact at the plasma membrane of living cells: A confocal fluorescence resonance energy transfer-based approach. The Journal of Biological Chemistry 2006, 281:37921-37929.
63. Ganju R.K., Dutt P., Wu L., Newman W., Avraham H., Avraham S., et al. Beta-chemokine receptor CCR5 signals via the novel tyrosine kinase RAFTK. Blood 1998, 91:791-797.
64. Ganju R.K., Brubaker S.A., Chernock R.D., Avraham S., Groopman J.E. Beta-chemokine receptor CCR5 signals through SHP1, SHP2, and Syk. The Journal of Biological Chemistry 2000, 275:17263-17268.
65. Garcia-Exposito L., Barroso-Gonzalez J., Puigdomenech I., Machado J.D., Blanco J., Valenzuela-Fernandez A. HIV-1 requires Arf6-mediated membrane dynamics to efficiently enter and infect T lymphocytes. Molecular Biology of the Cell 2011, 22:1148-1166.
66. Garcia-Perez J., Rueda P., Alcami J., Rognan D., Arenzana-Seisdedos F., Lagane B., et al. Allosteric model of maraviroc binding to CC chemokine receptor 5 (CCR5). The Journal of Biological Chemistry 2011, 286:33409-33421.
67. Garcia-Perez J., Rueda P., Staropoli I., Kellenberger E., Alcami J., Arenzana-Seisdedos F., et al. New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection. The Journal of Biological Chemistry 2011, 286:4978-4990.
68. Gilliam B.L., Riedel D.J., Redfield R.R. Clinical use of CCR5 inhibitors in HIV and beyond. Journal of Translational Medicine 2011, 9(Suppl. 1):S9.
69. Gomez-Mouton C., Lacalle R.A., Mira E., Jimenez-Baranda S., Barber D.F., Carrera A.C., et al. Dynamic redistribution of raft domains as an organizing platform for signaling during cell chemotaxis. The Journal of Cell Biology 2004, 164:759-768.
70. Gosling J., Monteclaro F.S., Atchison R.E., Arai H., Tsou C.L., Goldsmith M.A., et al. Molecular uncoupling of C-C chemokine receptor 5-induced chemotaxis and signal transduction from HIV-1 coreceptor activity. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:5061-5066.
71. Guergnon J., Combadiere C. Role of chemokines polymorphisms in diseases. Immunology Letters 2012, 145:15-22.
72. Hammad M.M., Kuang Y.Q., Yan R., Allen H., Dupre D.J. Na+/H+exchanger regulatory factor-1 is involved in chemokine receptor homodimer CCR5 internalization and signal transduction but does not affect CXCR4 homodimer or CXCR4-CCR5 heterodimer. The Journal of Biological Chemistry 2010, 285:34653-34664.
73. Harmon B., Ratner L. Induction of the Galpha(q) signaling cascade by the human immunodeficiency virus envelope is required for virus entry. Journal of Virology 2008, 82:9191-9205.
74. Harmon B., Campbell N., Ratner L. Role of Abl kinase and the Wave2 signaling complex in HIV-1 entry at a post-hemifusion step. PLoS Pathogens 2010, 6:e1000956.
75. Haworth B., Lin H., Fidock M., Dorr P., Strange P.G. Allosteric effects of antagonists on signalling by the chemokine receptor CCR5. Biochemical Pharmacology 2007, 74:891-897.
76. Hill C.M., Kwon D., Jones M., Davis C.B., Marmon S., Daugherty B.L., et al. The amino terminus of human CCR5 is required for its function as a receptor for diverse human and simian immunodeficiency virus envelope glycoproteins. Virology 1998, 248:357-371.
77. Hirsch E., Katanaev V.L., Garlanda C., Azzolino O., Pirola L., Silengo L., et al. Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science 2000, 287:1049-1053.
78. Hunt P.W., Shulman N.S., Hayes T.L., Dahl V., Somsouk M., Funderburg N.T., et al. The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: A randomized trial. Blood 2013, 121:4635-4646.
79. Huttenrauch F., Nitzki A., Lin F.T., Honing S., Oppermann M. Beta-arrestin binding to CC chemokine receptor 5 requires multiple C-terminal receptor phosphorylation sites and involves a conserved Asp-Arg-Tyr sequence motif. The Journal of Biological Chemistry 2002, 277:30769-30777.
80. Jacobson J.M., Saag M.S., Thompson M.A., Fischl M.A., Liporace R., Reichman R.C., et al. Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. The Journal of Infectious Diseases 2008, 198:1345-1352.
81. Jacobson J.M., Lalezari J.P., Thompson M.A., Fichtenbaum C.J., Saag M.S., Zingman B.S., et al. Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults. Antimicrobial Agents and Chemotherapy 2010, 54:4137-4142.
82. Jacobson J.M., Thompson M.A., Lalezari J.P., Saag M.S., Zingman B.S., D'Ambrosio P., et al. Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. The Journal of Infectious Diseases 2010, 201:1481-1487.
83. Jimenez-Baranda S., Gomez-Mouton C., Rojas A., Martinez-Prats L., Mira E., Ana Lacalle R., et al. Filamin-A regulates actin-dependent clustering of HIV receptors. Nature Cell Biology 2007, 9:838-846.
84. Jin T., Xu X., Hereld D. Chemotaxis, chemokine receptors and human disease. Cytokine 2008, 44:1-8.
85. Jolly C. T cell polarization at the virological synapse. Viruses 2010, 2:1261-1278.
86. Jones K.L., Maguire J.J., Davenport A.P. Chemokine receptor CCR5: From AIDS to atherosclerosis. British Journal of Pharmacology 2011, 162:1453-1469.
87. Juno J.A., Fowke K.R. Clarifying the role of G protein signaling in HIV infection: New approaches to an old question. AIDS Reviews 2010, 12:164-176.
88. Kazmierski W., Bifulco N., Yang H., Boone L., DeAnda F., Watson C., et al. Recent progress in discovery of small-molecule CCR5 chemokine receptor ligands as HIV-1 inhibitors. Bioorganic & Medicinal Chemistry 2003, 11:2663-2676.
89. Kenakin T. Drug efficacy at G protein-coupled receptors. Annual Review of Pharmacology and Toxicology 2002, 42:349-379.
90. Kindberg E., Mickiene A., Ax C., Akerlind B., Vene S., Lindquist L., et al. A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis. The Journal of Infectious Diseases 2008, 197:266-269.
91. Kinter A.L., Umscheid C.A., Arthos J., Cicala C., Lin Y., Jackson R., et al. HIV envelope induces virus expression from resting CD4+ T cells isolated from HIV-infected individuals in the absence of markers of cellular activation or apoptosis. Journal of Immunology 2003, 170:2449-2455.
92. Kondru R., Zhang J., Ji C., Mirzadegan T., Rotstein D., Sankuratri S., et al. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Molecular Pharmacology 2008, 73:789-800.
93. Kozak S.L., Heard J.M., Kabat D. Segregation of CD4 and CXCR4 into distinct lipid microdomains in T lymphocytes suggests a mechanism for membrane destabilization by human immunodeficiency virus. Journal of Virology 2002, 76:1802-1815.
94. Kraft K., Olbrich H., Majoul I., Mack M., Proudfoot A., Oppermann M. Characterization of sequence determinants within the carboxyl-terminal domain of chemokine receptor CCR5 that regulate signaling and receptor internalization. The Journal of Biological Chemistry 2001, 276:34408-34418.
95. Labrecque J., Metz M., Lau G., Darkes M.C., Wong R.S., Bogucki D., et al. HIV-1 entry inhibition by small-molecule CCR5 antagonists: A combined molecular modeling and mutant study using a high-throughput assay. Virology 2011, 413:231-243.
96. Lagane B., Ballet S., Planchenault T., Balabanian K., Le Poul E., Blanpain C., et al. Mutation of the DRY motif reveals different structural requirements for the CC chemokine receptor 5-mediated signaling and receptor endocytosis. Molecular Pharmacology 2005, 67:1966-1976.
97. Lagane B., Garcia-Perez J., Kellenberger E. Modeling the allosteric modulation of CCR5 function by Maraviroc. Drug Discovery Today: Technologies 2013, 10:e297-e305.
98. Lalezari J., Yadavalli G.K., Para M., Richmond G., Dejesus E., Brown S.J., et al. Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients. The Journal of Infectious Diseases 2008, 197:721-727.
99. Lalezari J., Gathe J., Brinson C., Thompson M., Cohen C., Dejesus E., et al. Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonist-naive subjects. Journal of Acquired Immune Deficiency Syndromes 2011, 57:118-125.
100. Latinovic O., Reitz M., Le N.M., Foulke J.S., Fatkenheuer G., Lehmann C., et al. CCR5 antibodies HGS004 and HGS101 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells. Virology 2011, 411:32-40.
101. Leach K., Charlton S.J., Strange P.G. Analysis of second messenger pathways stimulated by different chemokines acting at the chemokine receptor CCR5. Biochemical Pharmacology 2007, 74:881-890.
102. Lederman M.M., Veazey R.S., Offord R., Mosier D.E., Dufour J., Mefford M., et al. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 2004, 306:485-487.
103. Lederman M.M., Penn-Nicholson A., Cho M., Mosier D. Biology of CCR5 and its role in HIV infection and treatment. JAMA 2006, 296:815-826.
104. Lee B., Sharron M., Blanpain C., Doranz B.J., Vakili J., Setoh P., et al. Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. The Journal of Biological Chemistry 1999, 274:9617-9626.
105. Lee B., Sharron M., Montaner L.J., Weissman D., Doms R.W. Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:5215-5220.
106. Lee C., Liu Q.H., Tomkowicz B., Yi Y., Freedman B.D., Collman R.G. Macrophage activation through CCR5- and CXCR4-mediated gp120-elicited signaling pathways. Journal of Leukocyte Biology 2003, 74:676-682.
107. Lee C., Tomkowicz B., Freedman B.D., Collman R.G. HIV-1 gp120-induced TNF-{alpha} production by primary human macrophages is mediated by phosphatidylinositol-3 (PI-3) kinase and mitogen-activated protein (MAP) kinase pathways. Journal of Leukocyte Biology 2005, 78:1016-1023.
108. Li Z., Jiang H., Xie W., Zhang Z., Smrcka A.V., Wu D. Roles of PLC-beta2 and -beta3 and PI3Kgamma in chemoattractant-mediated signal transduction. Science 2000, 287:1046-1049.
109. Lim J.K., Murphy P.M. Chemokine control of West Nile virus infection. Experimental Cell Research 2011, 317:569-574.
110. Lim J.K., Glass W.G., McDermott D.H., Murphy P.M. CCR5: No longer a "good for nothing" gene-Chemokine control of West Nile virus infection. Trends in Immunology 2006, 27:308-312.
111. Lim J.K., Louie C.Y., Glaser C., Jean C., Johnson B., Johnson H., et al. Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: A meta-analysis of 4 cohorts in the US epidemic. The Journal of Infectious Diseases 2008, 197:262-265.
112. Lin Y.L., Mettling C., Portales P., Reynes J., Clot J., Corbeau P. Cell surface CCR5 density determines the postentry efficiency of R5 HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:15590-15595.
113. Lin Y.L., Mettling C., Portales P., Reant B., Clot J., Corbeau P. G-protein signaling triggered by R5 human immunodeficiency virus type 1 increases virus replication efficiency in primary T lymphocytes. Journal of Virology 2005, 79:7938-7941.
114. Lin Y.L., Mettling C., Portales P., Reant B., Robert-Hebmann V., Reynes J., et al. The efficiency of R5 HIV-1 infection is determined by CD4 T-cell surface CCR5 density through G alpha i-protein signalling. AIDS 2006, 20:1369-1377.
115. Liu R., Paxton W.A., Choe S., Ceradini D., Martin S.R., Horuk R., et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996, 86:367-377.
116. Lobritz M.A., Ratcliff A.N., Marozsan A.J., Dudley D.M., Tilton J.C., Arts E.J. Multifaceted mechanisms of HIV inhibition and resistance to CCR5 inhibitors PSC-RANTES and Maraviroc. Antimicrobial Agents and Chemotherapy 2013, 57:2640-2650.
117. Locati M., Murphy P.M. Chemokines and chemokine receptors: Biology and clinical relevance in inflammation and AIDS. Annual Review of Medicine 1999, 50:425-440.
118. Longden J., Cooke E.L., Hill S.J. Effect of CCR5 receptor antagonists on endocytosis of the human CCR5 receptor in CHO-K1 cells. British Journal of Pharmacology 2008, 153:1513-1527.
119. Lynch E.A., Heijens C.A., Horst N.F., Center D.M., Cruikshank W.W. Cutting edge: IL-16/CD4 preferentially induces Th1 cell migration: Requirement of CCR5. Journal of Immunology 2003, 171:4965-4968.
120. Macias J., Viloria M.M., Rivero A., de los Santos I., Marquez M., Portilla J., et al. Lack of short-term increase in serum mediators of fibrogenesis and in non-invasive markers of liver fibrosis in HIV/hepatitis C virus-coinfected patients starting maraviroc-based antiretroviral therapy. European Journal of Clinical Microbiology & Infectious Diseases 2012, 31:2083-2088.
121. Mack M., Luckow B., Nelson P.J., Cihak J., Simmons G., Clapham P.R., et al. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: A novel inhibitory mechanism of HIV infectivity. The Journal of Experimental Medicine 1998, 187:1215-1224.
122. Maeda K., Nakata H., Koh Y., Miyakawa T., Ogata H., Takaoka Y., et al. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. Journal of Virology 2004, 78:8654-8662.
123. Maeda K., Das D., Ogata-Aoki H., Nakata H., Miyakawa T., Tojo Y., et al. Structural and molecular interactions of CCR5 inhibitors with CCR5. The Journal of Biological Chemistry 2006, 281:12688-12698.
124. Malcolm R.K., Veazey R.S., Geer L., Lowry D., Fetherston S.M., Murphy D.J., et al. Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques. Antimicrobial Agents and Chemotherapy 2012, 56:2251-2258.
125. Manes S., Mira E., Gomez-Mouton C., Lacalle R.A., Keller P., Labrador J.P., et al. Membrane raft microdomains mediate front-rear polarity in migrating cells. EMBO Journal 1999, 18:6211-6220.
126. Manes S., del Real G., Lacalle R.A., Lucas P., Gomez-Mouton C., Sanchez-Palomino S., et al. Membrane raft microdomains mediate lateral assemblies required for HIV-1 infection. EMBO Reports 2000, 1:190-196.
127. Manes S., Gomez-Mouton C., Lacalle R.A., Jimenez-Baranda S., Mira E., Martinez A.C. Mastering time and space: Immune cell polarization and chemotaxis. Seminars in Immunology 2005, 17:77-86.
128. Marier J.F., Trinh M., Pheng L.H., Palleja S.M., Martin D.E. Pharmacokinetics and pharmacodynamics of TBR-652, a novel CCR5 antagonist, in HIV-1-infected, antiretroviral treatment-experienced, CCR5 antagonist-naive patients. Antimicrobial Agents and Chemotherapy 2011, 55:2768-2774.
129. Maung R., Medders K.E., Sejbuk N.E., Desai M.K., Russo R., Kaul M. Genetic knockouts suggest a critical role for HIV co-receptors in models of HIV gp120-induced brain injury. Journal of Neuroimmune Pharmacology 2012, 7:306-318.
130. Melar M., Ott D.E., Hope T.J. Physiological levels of virion-associated human immunodeficiency virus type 1 envelope induce coreceptor-dependent calcium flux. Journal of Virology 2007, 81:1773-1785.
131. Mettling C., Desmetz C., Fiser A.L., Reant B., Corbeau P., Lin Y.L. Galphai protein-dependant extracellular signal-regulated kinase-1/2 activation is required for HIV-1 reverse transcription. AIDS 2008, 22:1569-1576.
132. Min J., Defea K. Beta-arrestin-dependent actin reorganization: Bringing the right players together at the leading edge. Molecular Pharmacology 2011, 80:760-768.
133. Molon B., Gri G., Bettella M., Gomez-Mouton C., Lanzavecchia A., Martinez A.C., et al. T cell costimulation by chemokine receptors. Nature Immunology 2005, 6:465-471.
134. Mueller A., Strange P.G. CCL3, acting via the chemokine receptor CCR5, leads to independent activation of Janus kinase 2 (JAK2) and Gi proteins. FEBS Letters 2004, 570:126-132.
135. Mueller A., Kelly E., Strange P.G. Pathways for internalization and recycling of the chemokine receptor CCR5. Blood 2002, 99:785-791.
136. Mueller A., Mahmoud N.G., Goedecke M.C., McKeating J.A., Strange P.G. Pharmacological characterization of the chemokine receptor, CCR5. British Journal of Pharmacology 2002, 135:1033-1043.
137. Murphy P.M., Baggiolini M., Charo I.F., Hebert C.A., Horuk R., Matsushima K., et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacological Reviews 2000, 52:145-176.
138. Nedellec R., Coetzer M., Lederman M.M., Offord R.E., Hartley O., Mosier D.E. Resistance to the CCR5 Inhibitor 5P12-RANTES Requires a Difficult Evolution from CCR5 to CXCR4 Coreceptor Use. PLoS One 2011, 6:e22020.
139. Nguyen D.H., Taub D. Cholesterol is essential for macrophage inflammatory protein 1 beta binding and conformational integrity of CC chemokine receptor 5. Blood 2002, 99:4298-4306.
140. Nibbs R.J., Yang J., Landau N.R., Mao J.H., Graham G.J. LD78beta, a non-allelic variant of human MIP-1alpha (LD78alpha), has enhanced receptor interactions and potent HIV suppressive activity. The Journal of Biological Chemistry 1999, 274:17478-17483.
141. Nichols W.G., Steel H.M., Bonny T., Adkison K., Curtis L., Millard J., et al. Hepatotoxicity observed in clinical trials of aplaviroc (GW873140). Antimicrobial Agents and Chemotherapy 2008, 52:858-865.
142. Olbrich H., Proudfoot A.E., Oppermann M. Chemokine-induced phosphorylation of CC chemokine receptor 5 (CCR5). Journal of Leukocyte Biology 1999, 65:281-285.
143. Olson W.C., Rabut G.E., Nagashima K.A., Tran D.N., Anselma D.J., Monard S.P., et al. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. Journal of Virology 1999, 73:4145-4155.
144. Oppermann M., Mack M., Proudfoot A.E., Olbrich H. Differential effects of CC chemokines on CC chemokine receptor 5 (CCR5) phosphorylation and identification of phosphorylation sites on the CCR5 carboxyl terminus. The Journal of Biological Chemistry 1999, 274:8875-8885.
145. Palani A., Tagat J.R. Discovery and development of small-molecule chemokine coreceptor CCR5 antagonists. Journal of Medicinal Chemistry 2006, 49:2851-2857.
146. Park D., Jhon D.Y., Lee C.W., Lee K.H., Rhee S.G. Activation of phospholipase C isozymes by G protein beta gamma subunits. The Journal of Biological Chemistry 1993, 268:4573-4576.
147. Parker Z.F., Iyer S.S., Wilen C.B., Parrish N.F., Chikere K.C., Lee F.H., et al. Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5. Journal of Virology 2013, 87:2401-2411.
148. Partida-Sanchez S., Iribarren P., Moreno-Garcia M.E., Gao J.L., Murphy P.M., Oppenheimer N., et al. Chemotaxis and calcium responses of phagocytes to formyl peptide receptor ligands is differentially regulated by cyclic ADP ribose. Journal of Immunology 2004, 172:1896-1906.
149. Paruch S., Heinis M., Lemay J., Hoeffel G., Maranon C., Hosmalin A., et al. CCR5 signaling through phospholipase D involves p44/42 MAP-kinases and promotes HIV-1 LTR-directed gene expression. FASEB Journal 2007, 21:4038-4046.
150. Pease J., Horuk R. Chemokine receptor antagonists. Journal of Medicinal Chemistry 2012, 55:9363-9392.
151. Percherancier Y., Lagane B., Planchenault T., Staropoli I., Altmeyer R., Virelizier J.L., et al. HIV-1 entry into T-cells is not dependent on CD4 and CCR5 localization to sphingolipid-enriched, detergent-resistant, raft membrane domains. The Journal of Biological Chemistry 2003, 278:3153-3161.
152. Pichenot M., Deuffic-Burban S., Cuzin L., Yazdanpanah Y. Efficacy of new antiretroviral drugs in treatment-experienced HIV-infected patients: A systematic review and meta-analysis of recent randomized controlled trials. HIV Medicine 2012, 13:148-155.
153. Pike L.J. Lipid rafts: Heterogeneity on the high seas. The Biochemical Journal 2004, 378:281-292.
154. Pike L.J. Rafts defined: A report on the Keystone Symposium on Lipid Rafts and Cell Function. Journal of Lipid Research 2006, 47:1597-1598.
155. Ping L.H., Joseph S.B., Anderson J.A., Abrahams M.R., Salazar-Gonzalez J.F., Kincer L.P., et al. Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design. Journal of Virology 2013, 87:7218-7233.
156. Pollok-Kopp B., Schwarze K., Baradari V.K., Oppermann M. Analysis of ligand-stimulated CC chemokine receptor 5 (CCR5) phosphorylation in intact cells using phosphosite-specific antibodies. The Journal of Biological Chemistry 2003, 278:2190-2198.
157. Pontow S.E., Heyden N.V., Wei S., Ratner L. Actin cytoskeletal reorganizations and coreceptor-mediated activation of rac during human immunodeficiency virus-induced cell fusion. Journal of Virology 2004, 78:7138-7147.
158. Popik W., Alce T.M. CD4 receptor localized to non-raft membrane microdomains supports HIV-1 entry. Identification of a novel raft localization marker in CD4. The Journal of Biological Chemistry 2004, 279:704-712.
159. Portales P., Psomas K.C., Tuaillon E., Mura T., Vendrell J.P., Eliaou J.F., et al. The intensity of immune activation is linked to the level of CCR5 expression in human immunodeficiency virus type 1-infected persons. Immunology 2012, 137:89-97.
160. Procko E., McColl S.R. Leukocytes on the move with phosphoinositide 3-kinase and its downstream effectors. Bioessays 2005, 27:153-163.
161. Proudfoot A.E., Handel T.M., Johnson Z., Lau E.K., LiWang P., Clark-Lewis I., et al. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:1885-1890.
162. Pugach P., Marozsan A.J., Ketas T.J., Landes E.L., Moore J.P., Kuhmann S.E. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 2007, 361:212-228.
163. Putney L.K., Denker S.P., Barber D.L. The changing face of the Na+/H+exchanger, NHE1: Structure, regulation, and cellular actions. Annual Review of Pharmacology and Toxicology 2002, 42:527-552.
164. Raport C.J., Gosling J., Schweickart V.L., Gray P.W., Charo I.F. Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1beta, and MIP-1alpha. The Journal of Biological Chemistry 1996, 271:17161-17166.
165. Rawat S.S., Zimmerman C., Johnson B.T., Cho E., Lockett S.J., Blumenthal R., et al. Restricted lateral mobility of plasma membrane CD4 impairs HIV-1 envelope glycoprotein mediated fusion. Molecular Membrane Biology 2008, 25:83-94.
166. Reynes J., Portales P., Segondy M., Baillat V., Andre P., Reant B., et al. CD4+ T cell surface CCR5 density as a determining factor of virus load in persons infected with human immunodeficiency virus type 1. The Journal of Infectious Diseases 2000, 181:927-932.
167. Roche M., Jakobsen M.R., Sterjovski J., Ellett A., Posta F., Lee B., et al. HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism. Journal of Virology 2011, 85:4330-4342.
168. Rodriguez-Frade J.M., Vila-Coro A.J., Martin A., Nieto M., Sanchez-Madrid F., Proudfoot A.E., et al. Similarities and differences in RANTES- and (AOP)-RANTES-triggered signals: Implications for chemotaxis. The Journal of Cell Biology 1999, 144:755-765.
169. Rovati G.E., Capra V., Neubig R.R. The highly conserved DRY motif of class A G protein-coupled receptors: Beyond the ground state. Molecular Pharmacology 2007, 71:959-964.
170. Samama P., Cotecchia S., Costa T., Lefkowitz R.J. A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. The Journal of Biological Chemistry 1993, 268:4625-4636.
171. Samson M., Libert F., Doranz B.J., Rucker J., Liesnard C., Farber C.M., et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996, 382:722-725.
172. Schall T.J., Proudfoot A.E. Overcoming hurdles in developing successful drugs targeting chemokine receptors. Nature Reviews. Immunology 2011, 11:355-363.
173. Schnell G., Joseph S., Spudich S., Price R.W., Swanstrom R. HIV-1 replication in the central nervous system occurs in two distinct cell types. PLoS Pathogens 2011, 7:e1002286.
174. Schober A. Chemokines in vascular dysfunction and remodeling. Arteriosclerosis, Thrombosis, and Vascular Biology 2008, 28:1950-1959.
175. Scholten D.J., Canals M., Maussang D., Roumen L., Smit M.J., Wijtmans M., et al. Pharmacological modulation of chemokine receptor function. British Journal of Pharmacology 2012, 165:1617-1643.
176. Seibert C., Ying W., Gavrilov S., Tsamis F., Kuhmann S.E., Palani A., et al. Interaction of small molecule inhibitors of HIV-1 entry with CCR5. Virology 2006, 349:41-54.
177. Shi G., Partida-Sanchez S., Misra R.S., Tighe M., Borchers M.T., Lee J.J., et al. Identification of an alternative G{alpha}q-dependent chemokine receptor signal transduction pathway in dendritic cells and granulocytes. The Journal of Experimental Medicine 2007, 204:2705-2718.
178. Shideman C.R., Hu S., Peterson P.K., Thayer S.A. CCL5 evokes calcium signals in microglia through a kinase-, phosphoinositide-, and nucleotide-dependent mechanism. Journal of Neuroscience Research 2006, 83:1471-1484.
179. Shin N., Solomon K., Zhou N., Wang K.H., Garlapati V., Thomas B., et al. Identification and characterization of INCB9471, an allosteric noncompetitive small-molecule antagonist of C-C chemokine receptor 5 with potent inhibitory activity against monocyte migration and HIV-1 infection. The Journal of Pharmacology and Experimental Therapeutics 2011, 338:228-239.
180. Signoret N., Pelchen-Matthews A., Mack M., Proudfoot A.E., Marsh M. Endocytosis and recycling of the HIV coreceptor CCR5. The Journal of Cell Biology 2000, 151:1281-1294.
181. Signoret N., Hewlett L., Wavre S., Pelchen-Matthews A., Oppermann M., Marsh M. Agonist-induced endocytosis of CC chemokine receptor 5 is clathrin dependent. Molecular Biology of the Cell 2005, 16:902-917.
182. Simmons G., Clapham P.R., Picard L., Offord R.E., Rosenkilde M.M., Schwartz T.W., et al. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 1997, 276:276-279.
183. Sorce S., Myburgh R., Krause K.H. The chemokine receptor CCR5 in the central nervous system. Progress in Neurobiology 2011, 93:297-311.
184. Spadaro F., Cecchetti S., Purificato C., Sabbatucci M., Podo F., Ramoni C., et al. Nuclear phosphoinositide-specific phospholipase C beta1 controls cytoplasmic CCL2 mRNA levels in HIV-1 gp120-stimulated primary human macrophages. PLoS One 2013, 8:e59705.
185. Spear M., Guo J., Wu Y. The trinity of the cortical actin in the initiation of HIV-1 infection. Retrovirology 2012, 9:45.
186. Springael J.Y., de Poorter C., Deupi X., Van Durme J., Pardo L., Parmentier M. The activation mechanism of chemokine receptor CCR5 involves common structural changes but a different network of interhelical interactions relative to rhodopsin. Cellular Signalling 2007, 19:1446-1456.
187. Staudinger R., Phogat S.K., Xiao X., Wang X., Dimitrov D.S., Zolla-Pazner S. Evidence for CD4-enhanced signaling through the chemokine receptor CCR5. The Journal of Biological Chemistry 2003, 278:10389-10392.
188. Steen A., Thiele S., Guo D., Hansen L.S., Frimurer T.M., Rosenkilde M.M. Biased and constitutive signaling in the CC-chemokine receptor CCR5 by manipulating the interface between transmembrane helices 6 and 7. The Journal of Biological Chemistry 2013, 288:12511-12521.
189. Steffens C.M., Hope T.J. Localization of CD4 and CCR5 in living cells. Journal of Virology 2003, 77:4985-4991.
190. Steffens C.M., Hope T.J. Mobility of the human immunodeficiency virus (HIV) receptor CD4 and coreceptor CCR5 in living cells: Implications for HIV fusion and entry events. Journal of Virology 2004, 78:9573-9578.
191. Sun Y., Cheng Z., Ma L., Pei G. Beta-arrestin2 is critically involved in CXCR4-mediated chemotaxis, and this is mediated by its enhancement of p38 MAPK activation. The Journal of Biological Chemistry 2002, 277:49212-49219.
192. Tagat J.R., McCombie S.W., Nazareno D., Labroli M.A., Xiao Y., Steensma R.W., et al. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]- 4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperazinyl]- 4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist. Journal of Medicinal Chemistry 2004, 47:2405-2408.
193. Tan Q., Zhu Y., Li J., Chen Z., Han G.W., Kufareva I., et al. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science 2013, 341:1387-1390.
194. Taylor B.S., Wilkin T.J., Shalev N., Hammer S.M. CROI 2013: Advances in antiretroviral therapy. Topics in Antiviral Medicine 2013, 21:75-89.
195. Telenti A. Safety concerns about CCR5 as an antiviral target. Current Opinion in HIV and AIDS 2009, 4:131-135.
196. Thelen M. Dancing to the tune of chemokines. Nature Immunology 2001, 2:129-134.
197. Thiele S., Steen A., Jensen P.C., Mokrosinski J., Frimurer T.M., Rosenkilde M.M. Allosteric and orthosteric sites in CC chemokine receptor (CCR5), a chimeric receptor approach. The Journal of Biological Chemistry 2011, 286:37543-37554.
198. Tian Y., Lee M.M., Yung L.Y., Allen R.A., Slocombe P.M., Twomey B.M., et al. Differential involvement of Galpha16 in CC chemokine-induced stimulation of phospholipase Cbeta, ERK, and chemotaxis. Cellular Signalling 2008, 20:1179-1189.
199. Tilton J.C., Amrine-Madsen H., Miamidian J.L., Kitrinos K.M., Pfaff J., Demarest J.F., et al. HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry. AIDS Research and Human Retroviruses 2010, 26:13-24.
200. Tilton J.C., Wilen C.B., Didigu C.A., Sinha R., Harrison J.E., Agrawal-Gamse C., et al. A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5. Journal of Virology 2010, 84:10863-10876.
201. Tomkowicz B., Lee C., Ravyn V., Cheung R., Ptasznik A., Collman R.G. The Src kinase Lyn is required for CCR5 signaling in response to MIP-1beta and R5 HIV-1 gp120 in human macrophages. Blood 2006, 108:1145-1150.
202. Townson J.R., Graham G.J., Landau N.R., Rasala B., Nibbs R.J. Aminooxypentane addition to the chemokine macrophage inflammatory protein-1alpha P increases receptor affinities and HIV inhibition. The Journal of Biological Chemistry 2000, 275:39254-39261.
203. Trautmann A. Chemokines as immunotransmitters?. Nature Immunology 2005, 6:427-428.
204. Truan Z., Tarancon Diez L., Bonsch C., Malkusch S., Endesfelder U., Munteanu M., et al. Quantitative morphological analysis of arrestin2 clustering upon G protein-coupled receptor stimulation by super-resolution microscopy. Journal of Structural Biology 2013, 184:329-334.
205. Trzaskowski B., Latek D., Yuan S., Ghoshdastider U., Debinski A., Filipek S. Action of molecular switches in GPCRs-theoretical and experimental studies. Current Medicinal Chemistry 2012, 19:1090-1109.
206. Tsamis F., Gavrilov S., Kajumo F., Seibert C., Kuhmann S., Ketas T., et al. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. Journal of Virology 2003, 77:5201-5208.
207. Tsibris A.M., Sagar M., Gulick R.M., Su Z., Hughes M., Greaves W., et al. In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. Journal of Virology 2008, 82:8210-8214.
208. Turner L., Ward S.G., Sansom D., Westwick J. A role for RANTES in T lymphocyte proliferation. Biochemical Society Transactions 1996, 24:93S.
209. Vanpouille C., Arakelyan A., Margolis L. Microbicides: Still a long road to success. Trends in Microbiology 2012, 20:369-375.
210. van Wilgenburg B., Moore M.D., James W.S., Cowley S.A. The productive entry pathway of HIV-1 in macrophages is dependent on endocytosis through lipid rafts containing CD4. PLoS One 2014, 9:e86071.
211. Veazey R.S., Klasse P.J., Schader S.M., Hu Q., Ketas T.J., Lu M., et al. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 2005, 438:99-102.
212. Veazey R.S., Springer M.S., Marx P.A., Dufour J., Klasse P.J., Moore J.P. Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor. Nature Medicine 2005, 11:1293-1294.
213. Veazey R.S., Ling B., Green L.C., Ribka E.P., Lifson J.D., Piatak M., et al. Topically applied recombinant chemokine analogues fully protect macaques from vaginal simian-human immunodeficiency virus challenge. The Journal of Infectious Diseases 2009, 199:1525-1527.
214. Veazey R.S., Ketas T.J., Dufour J., Moroney-Rasmussen T., Green L.C., Klasse P.J., et al. Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. The Journal of Infectious Diseases 2010, 202:739-744.
215. Venkatesan S., Rose J.J., Lodge R., Murphy P.M., Foley J.F. Distinct mechanisms of agonist-induced endocytosis for human chemokine receptors CCR5 and CXCR4. Molecular Biology of the Cell 2003, 14:3305-3324.
216. Viard M., Parolini I., Sargiacomo M., Fecchi K., Ramoni C., Ablan S., et al. Role of cholesterol in human immunodeficiency virus type 1 envelope protein-mediated fusion with host cells. Journal of Virology 2002, 76:11584-11595.
217. Vila-Coro A.J., Mellado M., Martin de Ana A., Martinez A.C., Rodriguez-Frade J.M. Characterization of RANTES- and aminooxypentane-RANTES-triggered desensitization signals reveals differences in recruitment of the G protein-coupled receptor complex. Journal of Immunology 1999, 163:3037-3044.
218. Viola A., Luster A.D. Chemokines and their receptors: Drug targets in immunity and inflammation. Annual Review of Pharmacology and Toxicology 2008, 48:171-197.
219. Vorster P.J., Guo J., Yoder A., Wang W., Zheng Y., Xu X., et al. LIM kinase 1 modulates cortical actin and CXCR4 cycling and is activated by HIV-1 to initiate viral infection. The Journal of Biological Chemistry 2011, 286:12554-12564.
220. Vroon A., Heijnen C.J., Lombardi M.S., Cobelens P.M., Mayor F., Caron M.G., et al. Reduced GRK2 level in T cells potentiates chemotaxis and signaling in response to CCL4. Journal of Leukocyte Biology 2004, 75:901-909.
221. Waheed A.A., Freed E.O. Lipids and membrane microdomains in HIV-1 replication. Virus Research 2009, 143:162-176.
222. Wang W., Guo J., Yu D., Vorster P.J., Chen W., Wu Y. A dichotomy in cortical actin and chemotactic actin activity between human memory and naive T cells contributes to their differential susceptibility to HIV-1 infection. The Journal of Biological Chemistry 2012, 287:35455-35469.
223. Ward S.G. Do phosphoinositide 3-kinases direct lymphocyte navigation?. Trends in Immunology 2004, 25:67-74.
224. Watson C., Jenkinson S., Kazmierski W., Kenakin T. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Molecular Pharmacology 2005, 67:1268-1282.
225. Weissman D., Rabin R.L., Arthos J., Rubbert A., Dybul M., Swofford R., et al. Macrophage-tropic HIV and SIV envelope proteins induce a signal through the CCR5 chemokine receptor. Nature 1997, 389:981-985.
226. Westby M., Smith-Burchnell C., Mori J., Lewis M., Mosley M., Stockdale M., et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. Journal of Virology 2007, 81:2359-2371.
227. Wilen C.B., Tilton J.C., Doms R.W. HIV: Cell binding and entry. Cold Spring Harbor Perspectives in Medicine 2012, 2.
228. Wilkin T.J., Gulick R.M. CCR5 antagonism in HIV infection: Current concepts and future opportunities. Annual Review of Medicine 2012, 63:81-93.
229. Wong M., Uddin S., Majchrzak B., Huynh T., Proudfoot A.E., Platanias L.C., et al. Rantes activates Jak2 and Jak3 to regulate engagement of multiple signaling pathways in T cells. The Journal of Biological Chemistry 2001, 276:11427-11431.
230. Wu Y., Yoder A. Chemokine coreceptor signaling in HIV-1 infection and pathogenesis. PLoS Pathogens 2009, 5:e1000520.
231. Wu D., Katz A., Simon M.I. Activation of phospholipase C beta 2 by the alpha and beta gamma subunits of trimeric GTP-binding protein. Proceedings of the National Academy of Sciences of the United States of America 1993, 90:5297-5301.
232. Wu Y., Wang S., Farooq S.M., Castelvetere M.P., Hou Y., Gao J.L., et al. A chemokine receptor CXCR2 macromolecular complex regulates neutrophil functions in inflammatory diseases. The Journal of Biological Chemistry 2012, 287:5744-5755.
233. Xiao X., Wu L., Stantchev T.S., Feng Y.R., Ugolini S., Chen H., et al. Constitutive cell surface association between CD4 and CCR5. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:7496-7501.
234. Xiao X., Kinter A., Broder C.C., Dimitrov D.S. Interactions of CCR5 and CXCR4 with CD4 and gp120 in human blood monocyte-derived dendritic cells. Experimental and Molecular Pathology 2000, 68:133-138.
235. Yao X.J., Velez Ruiz G., Whorton M.R., Rasmussen S.G., DeVree B.T., Deupi X., et al. The effect of ligand efficacy on the formation and stability of a GPCR-G protein complex. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:9501-9506.
236. Yi L., Fang J., Isik N., Chim J., Jin T. HIV gp120-induced interaction between CD4 and CCR5 requires cholesterol-rich microenvironments revealed by live cell fluorescence resonance energy transfer imaging. The Journal of Biological Chemistry 2006, 281:35446-35453.
237. Zamilpa R., Kanakia R., Cigarroa J., Dai Q., Escobar G.P., Martinez H., et al. CC chemokine receptor 5 deletion impairs macrophage activation and induces adverse remodeling following myocardial infarction. American Journal of Physiology. Heart and Circulatory Physiology 2011, 300:H1418-H1426.
238. Zhao Q. Dual targeting of CCR2 and CCR5: Therapeutic potential for immunologic and cardiovascular diseases. Journal of Leukocyte Biology 2010, 88:41-55.
239. Zhao J., Ma L., Wu Y.L., Wang P., Hu W., Pei G. Chemokine receptor CCR5 functionally couples to inhibitory G proteins and undergoes desensitization. Journal of Cellular Biochemistry 1998, 71:36-45.
240. Zhong P., Agosto L.M., Munro J.B., Mothes W. Cell-to-cell transmission of viruses. Current Opinion in Virology 2013, 3:44-50.